Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$494.46 USD
-11.32 (-2.24%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $494.52 +0.06 (0.01%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRTX 494.46 -11.32(-2.24%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?
Other News for VRTX
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
3 Biotech Stocks That Could Have Investors Grinning Soon
Vertex Pharmaceuticals (NASDAQ:VRTX) Slides despite Raising Revenue Guidance
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight